Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16007443 | 0.91 | LMNA (0.54) | KMT2ALMNASMN1; SMN2HTTABCB1 | |
| SCHEMBL16007605 | 0.87 | LMNA (0.46) | KMT2ALMNASMN1; SMN2HTTABCB1 | |
| SCHEMBL16007494 | 0.85 | RORC (0.46) | LMNASMN1; SMN2HTTABCB1ABCG2 | |
| SCHEMBL16017808 | 0.82 | ALDH1A1 (0.45) | PDE4DADORA3NPSR1KMT2ARXFP1 | |
| SCHEMBL16017734 | 0.80 | KDM4E (0.41) | NPSR1KMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL16007500 | 0.78 | RORC (0.44) | LMNASMN1; SMN2HTTABCB1ABCG2 | |
| SCHEMBL16007649 | 0.76 | SLC6A12 (0.44) | KMT2ALMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL16007789 | 0.75 | TP53 (0.41) | KMT2ALMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL16007664 | 0.74 | POLB (0.59) | KMT2ARXFP1LMNASMN1; SMN2HTT | |
| SCHEMBL16007808 | 0.73 | ALDH1A1 (0.49) | KMT2ARXFP1LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227955-B2 | Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2016-01-05 | — | — | US | disclosed |
| US-9227955-B2 | Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2016-01-05 | — | — | US | disclosed |
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2014-09-11 | — | — | US | disclosed |
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | VEGFA, EDF1, FLT1 | PDE4D 1081/4885ADORA3 4115/4885NPSR1 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.